Merck KGaA reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

Merck KGaA’sMRK-1.94%decrease ... sales grow faster than previously expected over the medium term. The life-sciences and chemicals group lifted its mid-term outlook for its electronics business ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck MRK-1.63%decrease; red down pointing triangle KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a significant drop in profits in 2023. At an investment day at its headquarters ...

GERMAN science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for US$600 million, it said ahead of its Capital ...